First Oral HAE Tablet Reshapes Acute Attack Treatment Landscape

KalVista Pharmaceuticals' EKTERLY (sebetralstat) received FDA approval on July 3, 2025, as the first oral on-demand tablet indicated for acute hereditary angioedema attacks, shifting a treatment category long dominated by injectables toward solid-dose manufacturing. For plant heads and QA directors supplying rare disease portfolios, the approval signals immediate pressure to evaluate solid-dose scale-up pathways, tablet stability protocols, and GMP compliance frameworks suited to a patient population that now self-administers at first symptom recognition.

EKTERLY is a plasma kallikrein inhibitor dosed as two 600 mg tablets taken at the earliest recognition of an HAE attack, approved for adult and pediatric patients aged 12 years and older with HAE type I or II. The shift from parenteral to oral delivery introduces distinct process validation considerations: content uniformity across high-dose tablet batches, moisture-sensitive excipient management, and shelf-life stability data aligned with ICH Q1 guidelines for a product intended for home storage and on-demand use.

The pivotal KONFIDENT trial enrolled 110 patients across 66 sites in 20 countries, evaluating EKTERLY 600 mg, EKTERLY 300 mg, and placebo in a randomized crossover design. The primary endpoint measured time to sustained symptom relief, defined as at least two consecutive patient-reported assessments of feeling at least a little better within 12 hours of the first dose. Participants were required to have experienced at least two HAE attacks in the three months prior to enrollment. Most participants had HAE type I (92%), with 8% having HAE type II. At baseline, 78% were on on-demand therapy only and 22% were on chronic prophylaxis.

For regulatory affairs leads, the approval establishes a clinical data package built on a multinational trial spanning Australia, Bulgaria, Canada, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Romania, Slovakia, Spain, the United Kingdom, and the United States. Submissions referencing EKTERLY as a comparator or seeking line extensions in the HAE category will need to account for this cross-regional efficacy dataset and the patient-reported outcome instrument used to define the primary endpoint.

Source: FDA Drug Trials Snapshots: EKTERLY, published April 28, 2026, based on original approval date of July 3, 2025. KalVista Pharmaceuticals Limited.